ACS Biomaterials Science & Engineering · 2022 · 34 citations · 23 references
PharmacyMedicinal ChemistryOncologyDrug DeliveryNanomaterialsNanoparticle Drug DeliveryNanomedicineNanoparticle DesignPhotodynamic TherapyPhotothermal TherapyTargeted Cancer TherapyTargeted Imaging AgentsMolecular TargetingNanoparticle Imaging AgentsNanoparticle Imaging ProbesPhotodynamic Therapy NanomaterialsTargeted Photothermal TherapyTumor RetentionTumor SelectivityTumor Targeting Specificity
In nonsmall cell lung cancers (NSCLC), near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) has proven to be an efficient approach for locating pulmonary nodules and pulmonary sentinel lymph nodes. However, due to a lack of tumor selectivity, ICG’s use as a photosensitizer for photothermal therapy (PTT) and photodynamic therapy (PDT) is restricted. In the current study, we aimed to develop a type of high-performance NIR nanoparticle formulated with ICG to enhance its targeted efficacy and tumor specificity on NSCLC. An ICG-osimertinib nanoparticle (ICG-Osi) was self-assembled through π–π stacking, with a size of 276 nm and a surface charge of −7.4 mV. The NIR visibility and epidermal growth factor receptor (EGFR) targetability of the ICG-Osi was confirmed by its binding efficiency to EGFR-expressing NSCLC cells in vitro and in vivo, regardless of EGFR mutation status. The targeted effect was further confirmed in mouse xenograft models and showed an extended tumor retention time (>96 h). We demonstrated a significantly enhanced hyperthermia effect and a retained reactive oxygen species (ROS) generating ability of ICG-Osi, resulting in a 2-fold higher cell death rate than ICG alone. The ICG-Osi down-regulated GPX4 and p62 expression while up-regulating caspase-3 and beclin1 expression in NSCLC cells, indicating a complex network of cell death-related proteins. Considering the merits of simple assembly, EGFR binding efficacy, improved hyperthermia effect, and efficient cancer cell suppression, the ICG-Osi exhibits great potential for clinical application in EGFR-expressing NSCLC therapy.
23
RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer
Xinbing Sui, Ruonan Zhang, Shuiping Liu et al. · Frontiers in Pharmacology · 2018 · 698 citations · Full text
Medicine, Cancer Biology, Oncology +17